Fate Therapeutics Inc
FATE1.070USD
-0.030-2.73%
Cierre 08/01, 16:00（ET）Cotizaciones retrasadas 15 min
122.63MCap. mercado
PérdidaP/E TTM
Más Datos de Fate Therapeutics Inc Compañía
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Información de la empresa
Símbolo de cotizaciónFATE
Nombre de la empresaFate Therapeutics Inc
Fecha de salida a bolsaOct 01, 2013
Fundada en2007
Director ejecutivoDr. Bahram Valamehr, Ph.D.
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 01
Dirección12278 Scripps Summit Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92131
Teléfono18588751803
Sitio Webhttps://fatetherapeutics.com/
Símbolo de cotizaciónFATE
Fecha de salida a bolsaOct 01, 2013
Fundada en2007
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 22 de may
Actualizado: jue., 22 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Redmile Group, LLC
11.24%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
7.65%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
58.00%
Accionistas
Accionistas
Proporción
Redmile Group, LLC
11.24%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
7.65%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
58.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
33.06%
Investment Advisor/Hedge Fund
28.53%
Hedge Fund
19.14%
Research Firm
6.44%
Venture Capital
3.35%
Individual Investor
1.74%
Private Equity
1.47%
Bank and Trust
0.36%
Pension Fund
0.15%
Other
5.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
417
108.07M
94.28%
-29.73M
2025Q1
445
110.00M
95.96%
-29.05M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Redmile Group, LLC
12.87M
11.23%
--
--
Mar 31, 2025
ARK Investment Management LLC
10.31M
9%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
10.31M
8.99%
-22.58K
-0.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
7.32%
-99.57K
-1.17%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
7.79M
6.8%
+7.79M
--
Mar 31, 2025
Citadel Advisors LLC
4.29M
3.74%
-93.10K
-2.12%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
3.26M
2.84%
--
--
Mar 31, 2025
JP Morgan Asset Management
2.76M
2.41%
+1.63M
+144.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.59M
2.26%
-306.82K
-10.59%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.66%
WisdomTree BioRevolution Fund
0.65%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.66%
WisdomTree BioRevolution Fund
Proporción0.65%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Schwab U.S. Broad Market ETF
Proporción0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
iShares Genomics Immunology and Healthcare ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
